TW200602072A - Combination therapy for preventing or treating alzheimer's disease, and kit therefor - Google Patents

Combination therapy for preventing or treating alzheimer's disease, and kit therefor

Info

Publication number
TW200602072A
TW200602072A TW094120199A TW94120199A TW200602072A TW 200602072 A TW200602072 A TW 200602072A TW 094120199 A TW094120199 A TW 094120199A TW 94120199 A TW94120199 A TW 94120199A TW 200602072 A TW200602072 A TW 200602072A
Authority
TW
Taiwan
Prior art keywords
disease
preventing
treating alzheimer
combination therapy
kit therefor
Prior art date
Application number
TW094120199A
Other languages
English (en)
Chinese (zh)
Other versions
TWI350173B (enExample
Inventor
Frank Mattner
Walter Schmidt
Original Assignee
Frank Mattner
Walter Schmidt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Frank Mattner, Walter Schmidt filed Critical Frank Mattner
Publication of TW200602072A publication Critical patent/TW200602072A/zh
Application granted granted Critical
Publication of TWI350173B publication Critical patent/TWI350173B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • External Artificial Organs (AREA)
TW094120199A 2004-07-13 2005-06-17 Combination therapy for preventing or treating alzheimer's disease, and kit therefor TW200602072A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0118504A AT500483B1 (de) 2004-07-13 2004-07-13 Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung

Publications (2)

Publication Number Publication Date
TW200602072A true TW200602072A (en) 2006-01-16
TWI350173B TWI350173B (enExample) 2011-10-11

Family

ID=35115768

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094120199A TW200602072A (en) 2004-07-13 2005-06-17 Combination therapy for preventing or treating alzheimer's disease, and kit therefor

Country Status (14)

Country Link
US (2) US7935348B2 (enExample)
EP (1) EP1765388B8 (enExample)
JP (2) JP5642333B2 (enExample)
KR (1) KR101158600B1 (enExample)
CN (1) CN101022825B (enExample)
AT (1) AT500483B1 (enExample)
AU (1) AU2005261687B8 (enExample)
CA (1) CA2577332C (enExample)
DK (1) DK1765388T3 (enExample)
ES (1) ES2414872T3 (enExample)
PL (1) PL1765388T3 (enExample)
PT (1) PT1765388E (enExample)
TW (1) TW200602072A (enExample)
WO (1) WO2006005706A2 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056318A2 (en) 2002-12-19 2004-07-08 New York University Method for treating amyloid disease
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
AT500483B1 (de) * 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
KR20080090408A (ko) 2005-11-30 2008-10-08 아보트 러보러터리즈 항-Ａβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법
SG10201706600VA (en) 2005-11-30 2017-09-28 Abbvie Inc Monoclonal antibodies and uses thereof
US8455626B2 (en) * 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008080045A2 (en) * 2006-12-22 2008-07-03 Genentech, Inc. Dr6 antibodies inhibiting the binding of dr6 to app, and uses thereof in treating neurological disorders
WO2008104386A2 (en) * 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
EP2226081A4 (en) 2007-10-25 2011-10-12 Univ Kagoshima PEPTIDE VACCINE WITH A MIMIC MOLECULE OF AMYLOID PEPTIDE
ES2332846B1 (es) 2007-10-26 2010-07-08 Grifols, S.A. Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos.
AT506820B1 (de) * 2008-06-12 2011-07-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzine gegen alzheimer-krankheit
AT506819B1 (de) * 2008-06-12 2011-06-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzin zur behandlung von alzheimer-krankheit
EP2320987A1 (en) * 2008-07-29 2011-05-18 Medtronic, Inc. Apheresis of a target molecule from cerebrospinal fluid
HUE027027T2 (en) * 2008-11-13 2016-08-29 Modgene Llc Reduction of amyloid beta load in non-brain tissue
CN104274875A (zh) 2008-12-22 2015-01-14 学校法人藤田学园 Aβ 除去材料、Aβ 除去器和Aβ 除去系统
US20110033463A1 (en) * 2009-08-06 2011-02-10 Medtronic, Inc. Apheresis, administration of agent, or combination thereof
EP2558494B1 (en) 2010-04-15 2018-05-23 AbbVie Inc. Amyloid-beta binding proteins
JP5843345B2 (ja) 2010-07-08 2016-01-13 旭化成メディカル株式会社 β−アミロイド除去システム
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US20120321694A1 (en) * 2010-10-27 2012-12-20 Daniel Larocque Compositions and uses
DK2579042T3 (da) 2011-10-04 2014-07-21 Affiris Ag Fremgangsmåde til at påvise Aß-specifikke antistoffer i en biologisk prøve
MX352749B (es) 2011-11-01 2017-12-06 Modgene Llc Composiciones y metodos para la reduccion de la carga amiloide-beta.
CN110133298A (zh) * 2012-03-18 2019-08-16 株式会社资生堂 疾病样品分析装置、分析系统及分析方法
DE102012108598A1 (de) * 2012-09-14 2014-04-10 Forschungszentrum Jülich GmbH Neue, von D3 abgeleitete D-enantiomere Peptide und deren Verwendung
JP2015518474A (ja) * 2012-04-05 2015-07-02 フォルシュングスツェントルム ユーリッヒ ゲゼルシャフト ミット ベシュレンクテル ハフツングＦｏｒｓｃｈｕｎｇｓｚｅｎｔｒｕｍ Ｊｕｅｌｉｃｈ ＧｍｂＨ 血液、血液生産物及び器官を処置する方法
CN104380111B (zh) 2012-04-05 2017-08-29 于利希研究中心有限公司 包含多价结合淀粉样β蛋白的D‑肽的聚合物及其应用
KR101416954B1 (ko) * 2012-09-12 2014-07-16 한양대학교 산학협력단 조혈세포 분화 유도 방법
EP3116893B1 (en) * 2014-03-11 2019-08-28 Jacques Fantini A chimeric peptide that interacts with cell membrane gangliosides
CN106466298A (zh) * 2015-08-14 2017-03-01 上海交通大学医学院 一种单唾液酸四己糖神经节苷脂修饰的重组脂蛋白及其应用
CN109414482A (zh) * 2016-05-12 2019-03-01 俄亥俄州创新基金会 用于治疗神经退行性疾病的肽和方法
EP3655001A4 (en) * 2017-07-17 2021-04-28 Spark Therapeutics, Inc. Apheresis methods and uses
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
US12281166B2 (en) 2020-05-26 2025-04-22 Truebinding, Inc. Methods of treating inflammatory diseases by blocking Galectin-3
CN115957324A (zh) * 2021-10-12 2023-04-14 首都医科大学宣武医院 外周CLU作为靶点在降低脑Aβ中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476715A (en) 1989-10-03 1995-12-19 Fresenius Ag Particulate adsorbent for the removal of biomacromolecules such as LDL and endotoxins from whole blood in extracorporeal circuits
JP3161604B2 (ja) 1994-05-13 2001-04-25 プラズマセレクト ゲーエムベーハー テテロウ 血液中の物質を結合してそれを除去するためのタンパク質を結合させた、無菌かつ発熱物質を含有しないカラム
EP0886085B1 (en) 1997-06-18 2002-04-03 Morse Tec Europe S.p.A. Sprocket wheel with improved tooth profile for greater silentness
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6551266B1 (en) 1998-12-29 2003-04-22 Occulogix Corporation Rheological treatment methods and related apheresis systems
PE20020574A1 (es) * 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
ES2279869T3 (es) 2001-06-20 2007-09-01 Ramot At Tel Aviv University Ltd. Peptido antigenico comprendido por mulitples copias de un epitope de un polipeptido implicado en enfermedades de formacion de placas y los procedimientos de uso correspondientes.
US20050227941A1 (en) * 2001-12-17 2005-10-13 Karen Duff Sequestration of ass in the periphery in the absence of immunomodulating agent as a therapeutic approach for the treatment or prevention of beta-amyloid related diseases
CA2487528A1 (en) 2002-07-24 2004-02-12 Innogenetics N.V. Prevention, treatment and diagnosis of diseases associated with beta-amyloid formation and/or aggregation
WO2004056318A2 (en) * 2002-12-19 2004-07-08 New York University Method for treating amyloid disease
AT413945B (de) * 2003-01-14 2006-07-15 Mattner Frank Dr Impfstoff für die alzheimer-krankheit
PL378571A1 (pl) * 2003-02-01 2006-05-02 Neuralab Limited Czynna immunizacja dla wytworzenia przeciwciał przeciw rozpuszczalnemu A-ß
AT413336B (de) * 2003-09-12 2006-02-15 Mattner Frank Dr Apherese-vorrichtung
US20050158306A1 (en) * 2004-01-16 2005-07-21 Halikas James A. Treatment for neuro-degenerative disease by a blood cleansing system using monoclonal antibodies
AT413946B (de) * 2004-07-13 2006-07-15 Mattner Frank Dr Impfstoff gegen die alzheimer-krankheit
AT500483B1 (de) * 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
AT500835B1 (de) * 2004-09-13 2007-12-15 Affiris Forschungs & Entwicklungs Gmbh Cholinestertransport-protein-mimotop als atherosklerose-medikament

Also Published As

Publication number Publication date
KR101158600B1 (ko) 2012-07-09
US7935348B2 (en) 2011-05-03
DK1765388T3 (da) 2013-07-22
AT500483B1 (de) 2006-01-15
KR20070036158A (ko) 2007-04-02
CA2577332A1 (en) 2006-01-19
JP2008506665A (ja) 2008-03-06
TWI350173B (enExample) 2011-10-11
JP5642333B2 (ja) 2014-12-17
JP2013116903A (ja) 2013-06-13
AU2005261687B8 (en) 2011-07-21
AU2005261687B2 (en) 2011-02-17
ES2414872T3 (es) 2013-07-23
EP1765388B1 (de) 2013-04-17
US20110201987A1 (en) 2011-08-18
CA2577332C (en) 2014-12-09
EP1765388B8 (de) 2013-05-29
HK1103354A1 (en) 2007-12-21
PL1765388T3 (pl) 2013-09-30
AT500483A4 (de) 2006-01-15
CN101022825A (zh) 2007-08-22
PT1765388E (pt) 2013-05-24
US20080051690A1 (en) 2008-02-28
CN101022825B (zh) 2015-02-04
AU2005261687A1 (en) 2006-01-19
WO2006005706A3 (de) 2006-07-20
WO2006005706A8 (de) 2006-11-16
WO2006005706A2 (de) 2006-01-19
EP1765388A2 (de) 2007-03-28
ES2414872T8 (es) 2014-11-06

Similar Documents

Publication Publication Date Title
TW200602072A (en) Combination therapy for preventing or treating alzheimer's disease, and kit therefor
MX2020009668A (es) Métodos novedosos.
MX2020013335A (es) Metodos novedosos.
EP1613347A4 (en) BETA AMYLOID PEPTIDE DETECTING HUMANIZED ANTIBODIES
WO2008050148A3 (en) Therapy for liver disease
PL374865A1 (en) Treatment of tnf alpha related disorders
TW200509958A (en) Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
IL158921A0 (en) Anti-ngf antibodies for the treatment of various disorders
EP1755458A4 (en) METHOD AND DEVICE FOR THE SELECTIVE TREATMENT OF TISSUE
MXPA05010914A (es) Metodo de tratamiento de la enfermedad de alzheimer.
EA200401525A1 (ru) Способы лечения гепатита (варианты )
MX2007000606A (es) Arilidenos para el tratamiento de enfermedades mediadas por receptor alfa relacionado con estrogeno.
TW200637574A (en) Treatment method
EP2279742A3 (en) Combinations for the treatment of immunoinflammatory disorders
MX2009003532A (es) Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina.
PL1663347T3 (pl) Urządzenie do rozdzielania elementów krwi
NO20081835L (no) Behandlingsmetoder ved bruk av oksytocin receptoragonister
TW200531700A (en) Uses of melanocortin-4 receptor (MC4R) agonist peptides administered by continuous infusion
WO2006023452A3 (en) Cyclosporin analogs for the treatment of immunoregulatory disorders and respiratory diseases
EA200600989A1 (ru) Применение габоксадола для лечения бессонницы
MXPA05013975A (es) Tratamiento de enfermedades asociadas con amiloide y epileptogenesis.
IL170519A0 (en) Use of a fibrate and orlistat for the treatment of obesity
DE60215219D1 (de) Verwendung von darifenacin zur behandlung des harndrangs
SG156658A1 (en) Treatment of diseases
TW200509882A (en) Beauty method

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees